Neuropathic Pain Database
This trial is active, not recruiting.
|Sponsor||Lawson Health Research Institute|
|Collaborator||Canada Foundation for Innovation|
|Start date||April 2008|
|End date||December 2012|
|Trial size||900 participants|
|Trial identifier||NCT00669006, 13930E, R-07-835|
To establish the infrastructure for a national neuropathic pain database.
To determine the longterm outcome of the management of chronic neuropathic pain including pain relief, disability, and quality of life.
New patients with a diagnosis of Neuropathic Pain
To establish the infrastructure for a national Neuropathic Pain Database.
time frame: 2 years
To determine the longterm outcome of the management of chronic neuropathic pain including pain relief, disability and quality of life.
time frame: 2 years
Male or female participants of any age.
Inclusion Criteria: - Primarily Neuropathic Pain - Able to give informed consent - Estimated Life Expectancy of 2 years Exclusion Criteria: - Not primarily neuropathic pain - Declined participation- too much traveling - Declined participation- Unknown - Declined participation- Other, specify - Considered unreliable- personality disorder - Considered unreliable- cognitive impairment - Considered unreliable- substance abuse - Considered unreliable- Other - Language barrier - Exceeded quarterly quota - Presentation with progressive or recurrent cancer, fibromyalgia, perineal pain of unknown etiology - Other, specify
|Official title||National Neuropathic Pain Database Study|
|Principal investigator||Dwight Moulin, MD|
|Description||The database will provide standard information on demographics, diagnosis, treatment interventions and outcome modeled on guidelines from the expert panel on initiatives on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT)(Turk et al.,Pain 2003;106:337-345) The IMMPACT panel determined that patients should be evaluated according to six core domains as follows: Pain, physical functioning, emotional functioning, subject rating of global satisfaction with treatment, symptoms and adverse events and subject disposition. The database will allow us to examine outcomes based on single (eg. pregabalin) and multiple (e.g tricyclic antidepressants and gabalin) therapeutic interventions. Standard guidelines for management of neuropathic pain acknowledge that polypharmacy is appropriate when individual first line treatments fail to provide adequate pain relief (Gilron I et al., CMAJ 2006; 175: 265-275; Attal N et al., European Journal of Neurology 2006; 13: 1153-1169)|
Call for more information